PANA Insider Trading Activity and SEC Form 4 Filings
PANA insider trading summary
No open-market insider purchases or sales of Panacea Acquisition Corp. II (PANA) have been reported on SEC Form 4 in the past 12 months.
Latest PANA insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Apr 9, 2021 | EcoR1 Panacea Holdings II, LLC | Director | Buy | $5.5M (545,000 @ $10.00) |
| Apr 9, 2021 | EcoR1 Capital Fund, L.P. | Director | Buy | $5.5M (545,000 @ $10.00) |
| Apr 9, 2021 | EcoR1 Capital, LLC | Director | Buy | $5.5M (545,000 @ $10.00) |
| Apr 9, 2021 | EcoR1 Capital Fund Qualified, L.P. | Director | Buy | $5.5M (545,000 @ $10.00) |
| Apr 9, 2021 | EcoR1 Venture Opportunity Fund, LP | Director | Buy | $5.5M (545,000 @ $10.00) |
| Apr 9, 2021 | Oleg Nodelman | CEO and Chairman of the Board | Buy | $5.5M (545,000 @ $10.00) |
| Apr 9, 2021 | Biotech Opportunity GP, LLC | Director | Buy | $5.5M (545,000 @ $10.00) |
| Jul 6, 2020 | EcoR1 Capital Fund, L.P. | Director | Buy | $3.9M (390,000 @ $10.00) |
| Jul 6, 2020 | EcoR1 Capital, LLC | Director | Buy | $3.9M (390,000 @ $10.00) |
| Jul 6, 2020 | EcoR1 Panacea Holdings, LLC | Director | Buy | $3.9M (390,000 @ $10.00) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.